A covalent irreversible inhibitor binds in two mutually exclusive conformations to the active-site cysteine residue of human aldehyde dehydrogenase 1A3
Authors:
- Daniela CovaledaDCDaniela Covaleda
- David VizarragaDVDavid Vizarraga
- Tulsi UpadhyayTUTulsi Upadhyay
- Jiyun ZhuJZJiyun Zhu
- Daniel AbeggDADaniel Abegg
- Raquel PequerulRPRaquel Pequerul
- Martín HugoMHMartín Hugo
- Alexander AdibekianAAAlexander Adibekian
- Ignacio FitaIFIgnacio Fita
- Xavier ParésXPXavier Parés
- Francesc Xavier AvilésFrancesc Xavier Avilés
- Matthew BogyoMBMatthew Bogyo
Preprint
Abstract
Aldehyde dehydrogenases (ALDH) are enzymes that catalyze the NAD(P) + -dependent oxidation of aldehydes into carboxylic acids, playing roles in detoxification, biosynthesis, and regulatory functions. Dysfunction of ALDH is associated with serious conditions such as alcohol intolerance, cancer, cardiovascular problems, and neurological disorders. In humans, ALDH1A1 and ALDH1A3 isoforms act as retinaldehyde dehydrogenases and are overexpressed in various cancers, where high levels are associated with increased tumor malignancy, cancer stem cell traits, and therapeutic resistance. ALDH1A3 is recognized as a promising target for anticancer therapies, with several inhibitors, mainly reversible, developed to specifically target it or the enzyme family. Since ALDH enzymes can also display esterase activity, we used this property to develop an in vitro assay specifically targeting the esterase function of ALDH1A3. A highly conserved active-site cysteine in ALDH1A3 is located at the bottom of two converging channels, which define the substrate- and cofactor-binding pockets. To target this catalytic cysteine, we screened a library of 3,200 cysteine-focused covalent fragments. This led to the identification of Z3405279217 (Z34), an acrylamide-based covalent compound that inhibits both ALDH1A1 and ALDH1A3 at sub-micromolar levels. Biochemical and biophysical tests confirmed that Z34 acts as a time-dependent, covalent, and irreversible binder to the active-site cysteine. In this work, we determined the Cryo-EM structure of the ALDH1A3-Z34 complex at 2.26 Å resolution, confirming the covalent attachment to the catalytic cysteine of Z34. Notably, two mutually exclusive covalent binding modes were observed: one occupying the substrate-binding pocket and the other the cofactor-binding region. Z34 displayed unexpected binding modes within the active site and holds promise as a lead compound for future drug development. GRAPHICALKeywords
This publication has 61 references indexed in Scilit:
- Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemiaHemaSphere, 2025
- Discovery of a reversible ALDH1A3 inhibitor through a consensus docking-based virtual screening studyJournal of Computer-Aided Molecular Design, 2025
- Piperlonguminine a new mitochondrial aldehyde dehydrogenase activator protects the heart from ischemia/reperfusion injuryBiochimica et Biophysica Acta (BBA) - General Subjects, 2020
- Structural and kinetic features of aldehyde dehydrogenase 1A (ALDH1A) subfamily members, cancer stem cell markers active in retinoic acid biosynthesisArchives of Biochemistry and Biophysics, 2020
- Omeprazole as a potent activator of human cytosolic aldehyde dehydrogenase ALDH1A1Biochimica et Biophysica Acta (BBA) - General Subjects, 2020
- Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cellsCancer Letters, 2018
- Structural, Biochemical, and Computational Studies Reveal the Mechanism of Selective Aldehyde Dehydrogenase 1A1 Inhibition by Cytotoxic Duocarmycin AnaloguesAngewandte Chemie, 2015
- Tamoxifen, an anticancer drug, is an activator of human aldehyde dehydrogenase 1A1Proteins: Structure, Function, and Bioinformatics, 2014
- Design and Implementation of High-Throughput Screening Assays2009
- Spontaneous α-N-6-Phosphogluconoylation of a “His Tag” inEscherichia coli:The Cause of Extra Mass of 258 or 178 Da in Fusion ProteinsAnalytical Biochemistry, 1999